Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy

Overview

Journal Circ Arrhythm Electrophysiol

Date 2025 Feb 3

PMID 39895487

Authors

Omar M Abdelfattah

Ahmed Sayed

Ahmed Al-Jwaid

Ahmed Hassan

Deaa Abu Jazar

Arun Narayanan

Mark S Link

Matthew W Martinez

Affiliations

Soon will be listed here.

Abstract

Background: Over the past decades, hypertrophic cardiomyopathy has become a contemporary treatable disease. However, limited data exist on the global trends of implantable cardioverter defibrillator (ICD) utilization and its impact on mortality/morbidity burden reduction.

Methods: Electronic databases were systematically searched up to March 2024 for studies reporting on ICD utilization rates in hypertrophic cardiomyopathy. A random effects model was used to pool study estimates across time-era, geographic region, and age group. Primary outcome was global trends in ICD utilization. Secondary outcomes included trends of sudden cardiac death, appropriate/inappropriate shocks, and ICD-related complications.

Results: In total, 234 studies (N=92 500, 514 748 patient-years) met inclusion criteria. Mean age was 46.2 (12.4) years and 37.49% were women. A total of 12 139 patients (16.43%) received an ICD over 429 766 person-years of follow-up, with an ICD implantation rate of 2.79%/y ([95% CI, 2.35%-3.32%] I²=97.80%). Rates of ICD implantation steadily increased over time from 1990 (1.09%) to 2021 (4.01%; =0.002), with noticeable geographic variation (=0.008). The overall rate of appropriate ICD discharges and ICD-related complications was 3.44%/y ([95% CI, 3.08%-3.84%] I²=88.40%) and 1.98%/y ([95% CI, 1.52%-2.59%] I²=90.44%), respectively, with no significant trend over time. The overall rate of inappropriate discharges was 3.58%/y ([95% CI, 3.08%-4.16%] I=88.03%), and declined significantly over time (=0.044). There was a significant decline in the rates of sudden cardiac death from 1990 (0.84%/y) to 2020 (0.31%/y).

Conclusions: Dramatic increases in ICD utilization have occurred, representing a 3.7-fold increase, with appropriate therapies occurring in 3.44%/y. In parallel a significant reduction in sudden cardiac death was observed, but there are insufficient data to demonstrate that a causative relationship exists. Geographic disparities in ICD utilization were evident, highlighting the need to improve access to specialized care for patients with hypertrophic cardiomyopathy. Geographic disparities in ICD utilization were evident, highlighting the need to improve access to specialized care for patients with hypertrophic cardiomyopathy.

Registration: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42023407126.

References

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

Thavikulwat A, Tomson T, Knight B, Bonow R, Choudhury L . Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol. 2016; 27(8):953-60. DOI: 10.1111/jce.13005. View

Rowin E, Maron M, Adler A, Albano A, Varnava A, Spears D . Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2021; 19(5):782-789. DOI: 10.1016/j.hrthm.2021.12.017. View

Veselka J, Krejci J, Tomasov P, Jahnlova D, Honek T, Januska J . Survival of patients ≤ 50 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2014; 30(6):634-8. DOI: 10.1016/j.cjca.2014.03.041. View

Monserrat L, Elliott P, Gimeno J, Sharma S, Penas-Lado M, McKenna W . Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42(5):873-9. DOI: 10.1016/s0735-1097(03)00827-1. View

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

Klarich K, Attenhofer Jost C, Binder J, Connolly H, Scott C, Freeman W . Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol. 2013; 111(12):1784-91. DOI: 10.1016/j.amjcard.2013.02.040. View

Ntusi N, Sliwa K . Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy: JACC Focus Seminar 6/9. J Am Coll Cardiol. 2021; 78(25):2573-2579. DOI: 10.1016/j.jacc.2021.10.020. View

Shiozaki A, Senra T, Arteaga E, Martinelli Filho M, Pita C, Avila L . Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013; 7(3):173-81. PMC: 4128834. DOI: 10.1016/j.jcct.2013.04.002. View

10.

Gimeno J, Elliott P, Tavazzi L, Tendera M, Kaski J, Laroche C . Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. Eur Heart J Qual Care Clin Outcomes. 2020; 7(2):134-142. PMC: 7962774. DOI: 10.1093/ehjqcco/qcaa075. View

11.

Higuchi S, Minami Y, Shoda M, Shirotani S, Kanai M, Kataoka S . Effect of Renal Dysfunction on Risk of Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020; 144:131-136. DOI: 10.1016/j.amjcard.2020.12.063. View

12.

Ziolkowska L, Turska-Kmiec A, Petryka J, Kawalec W . Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy. Pediatr Cardiol. 2015; 37(3):448-58. PMC: 4819755. DOI: 10.1007/s00246-015-1298-y. View

13.

Maron B, Casey S, Chan R, Garberich R, Rowin E, Maron M . Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015; 116(5):757-64. DOI: 10.1016/j.amjcard.2015.05.047. View

14.

Maron B, Shen W, Link M, EPSTEIN A, Almquist A, Daubert J . Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(6):365-73. DOI: 10.1056/NEJM200002103420601. View

15.

Sakhi R, Huurman R, Theuns D, Schinkel A, Assaf A, Szili-Torok T . Incremental Value of an Insertable Cardiac Monitor in Patients with Hypertrophic Cardiomyopathy with Low or Intermediate Risk for Sudden Cardiac Death. Cardiology. 2021; 146(2):207-212. PMC: 8117374. DOI: 10.1159/000512656. View

16.

Altarabsheh S, Dearani J, Burkhart H, Schaff H, Deo S, Eidem B . Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults. Ann Thorac Surg. 2012; 95(2):663-9. DOI: 10.1016/j.athoracsur.2012.08.011. View

17.

Tunca Sahin G, Ozgur S, Kafali H, Sevinc Sengul F, Haydin S, Guzeltas A . Clinical characteristics of hypertrophic cardiomyopathy in children: An 8-year single center experience. Pediatr Int. 2020; 63(1):37-45. DOI: 10.1111/ped.14393. View

18.

Leong K, Chow J, Ng F, Falaschetti E, Qureshi N, Koa-Wing M . Comparison of the Prognostic Usefulness of the European Society of Cardiology and American Heart Association/American College of Cardiology Foundation Risk Stratification Systems for Patients With Hypertrophic Cardiomyopathy. Am J Cardiol. 2017; 121(3):349-355. PMC: 5812921. DOI: 10.1016/j.amjcard.2017.10.027. View

19.

Maron B, Spirito P, Ackerman M, Casey S, Semsarian C, Estes 3rd N . Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013; 61(14):1527-35. DOI: 10.1016/j.jacc.2013.01.037. View

20.

Prinz C, Vogt J, Bitter T, Muntean B, Hering D, Horstkotte D . Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death. Acta Cardiol. 2010; 65(5):521-5. DOI: 10.1080/ac.65.5.2056238. View